.png)
MiCAN Technologies
MiCAN Technologies has technologies and licenses to produce high function human myeloid lineage cells (Mylc) from human iPS cells. The development and the feasibility studies to launch the cMylc has been conducted with a collaboration to the Research Institute for Microbial Diseases at Osaka University.
ビジネス情報
会社名
MiCAN Technologies
設立
2016
位置
Kyoto, JP
からのスピンアウト
Independent
その他の場所
Kobe, JP
テクノロジーの検証
TRL
7
特許の価値
No data
ビジネスステージ
Spinout / Seed fund stage
ターゲット出口
IPO in other country
次の投資要件
ビジネスパートナーへのメッセージ
MiCAN is looking for global R&D partners to evaluate our iPS derived dendric myeloid cells in the applications of dengue virus and COVID-19 (SARS-CoV-2) research. Also looking for global supply chain partners (distributors) to handle our ready-to-use kit accessible to the global scientists.